المؤلفون: Normann LS, Haugen MH, Aure MR, Kristensen VN, Mælandsmo GM, Sahlberg KK

المصدر: Breast Cancer: Targets and Therapy, Vol Volume 14, Pp 25-39 (2022)

مصطلحات موضوعية: microrna, targeted treatment, apoptosis, sensitize, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.dovepress.com/mir-101-5p-acts-as-a-tumor-suppressor-in-her2-positive-breast-cancer-c-peer-reviewed-fulltext-article-BCTT; https://doaj.org/toc/1179-1314

URL الوصول: https://doaj.org/article/a894b8e4b1064711bfeb982a97bdaad0

المؤلفون: Haugen, MH, Gythfeldt, HV, Egeland, EV, Normann, LS, Pandya, AD, Vedin, LL, Juell, S, Tenstad, E, Oy, GF, Kristian, A, Marangoni, E, Sorlie, T, Steffensen, K, Maelandsmo, GM, Engebraaten, O

المصدر: Molecular oncology. 17(10):2041-2055

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:153038830

المؤلفون: Fleischer, T, Haugen, MH, Ankill, J, Silwal-Pandit, L, Borresen-Dale, AL, Hedenfalk, I, Hatschek, T, Tost, J, Engebraaten, O, Kristensen, VN

المصدر: Molecular oncology. 18(8):2042-2059

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:155778705

المؤلفون: Johansson, HJ, Socciarelli, F, Vacanti, NM, Haugen, MH, Zhu, Y, Siavelis, I, Fernandez-Woodbridge, A, Aure, MR, Sennblad, B, Vesterlund, M, Branca, RM, Orre, LM, Huss, M, Fredlund, E, Beraki, E, Garred, O, Boekel, J, Sauer, T, Zhao, W, Nord, S, Hoglander, EK, Jans, DC, Brismar, H, Haukaas, TH, Bathen, TF, Schlichting, E, Naume, B, Geisler, J, Hofvind, S, Engebraten, O, Geitvik, GA, Langerod, A, Karesen, R, Maelandsmo, GM, Sorlie, T, Skjerven, HK, Park, D, Hartman-Johnsen, OJ, Luders, T, Borgen, E, Kristensen, VN, Russnes, HG, Lingjaerde, OC, Mills, GB, Sahlberg, KK, Borresen-Dale, AL, Lehtio, J

المصدر: Nature communications. 10(1):1600

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:140686635

المؤلفون: Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad ø, Maelandsmo GM, Solberg R, Briggs, Jon J, Haugen, Mads H, Johansen, Harald T, Riker, Adam I, Abrahamson, Magnus, Fodstad, Øystein, Maelandsmo, Gunhild M, Solberg, Rigmor

المصدر: BMC Cancer; 2010, Vol. 10, p17-17, 1p

المؤلفون: Nygaard V; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Ree AH; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Dagenborg VJ; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Gastroenterological Surgery, Oslo University Hospital, Oslo, Norway., Børresen-Dale AL; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Edwin B; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway.; The Intervention Center, Oslo University Hospital, Oslo, Norway., Fretland ÅA; Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway.; The Intervention Center, Oslo University Hospital, Oslo, Norway., Grzyb K; Department of Pathology, Oslo University Hospital, Oslo, Norway., Haugen MH; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Mælandsmo GM; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Institute for Medical Biology, Faculty of Health Sciences, UiT-The Arctic University of Norway, Tromsø, Norway., Flatmark K; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Gastroenterological Surgery, Oslo University Hospital, Oslo, Norway.

المصدر: Cancer research communications [Cancer Res Commun] 2023 Feb 09; Vol. 3 (2), pp. 235-244. Date of Electronic Publication: 2023 Feb 09 (Print Publication: 2023).

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun

مواضيع طبية MeSH: Colorectal Neoplasms*/genetics , Liver Neoplasms*/genetics, Humans ; B7-H1 Antigen/genetics ; Hepatitis A Virus Cellular Receptor 2/genetics ; Programmed Cell Death 1 Receptor/genetics ; Neoplasm Recurrence, Local/genetics ; Microsatellite Repeats ; Tumor Microenvironment/genetics ; Homeodomain Proteins/genetics

المؤلفون: Normann LS; Department of Research and Innovation, Vestre Viken Hospital Trust, Drammen, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway., Haugen MH; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Hongisto V; Division of Toxicology, Misvik Biology, Turku, Finland., Aure MR; Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway., Leivonen SK; Applied Tumor Genomics Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland., Kristensen VN; Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway., Tahiri A; Department of Research and Innovation, Vestre Viken Hospital Trust, Drammen, Norway., Engebraaten O; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Sahlberg KK; Department of Research and Innovation, Vestre Viken Hospital Trust, Drammen, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Mælandsmo GM; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Institute for Medical Biology, Faculty of Health Sciences, UiT-The Arctic University of Norway, Tromsø, Norway.

المصدر: PloS one [PLoS One] 2023 Jan 27; Vol. 18 (1), pp. e0280507. Date of Electronic Publication: 2023 Jan 27 (Print Publication: 2023).

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use, Humans ; Female ; Lapatinib/pharmacology ; Lapatinib/therapeutic use ; Dasatinib/pharmacology ; Dasatinib/therapeutic use ; Quinazolines/pharmacology ; Quinazolines/therapeutic use ; Receptor, ErbB-2/metabolism ; Antibodies, Monoclonal, Humanized/therapeutic use ; Cell Line, Tumor ; Trastuzumab/therapeutic use

المؤلفون: Nyakas M; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Ullernchausseen 70, 0379, Oslo, Norway.; Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Fleten KG; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Ullernchausseen 70, 0379, Oslo, Norway., Haugen MH; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Ullernchausseen 70, 0379, Oslo, Norway., Engedal N; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Ullernchausseen 70, 0379, Oslo, Norway., Sveen C; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Ullernchausseen 70, 0379, Oslo, Norway., Farstad IN; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Oslo, Norway., Flørenes VA; Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway., Prasmickaite L; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Ullernchausseen 70, 0379, Oslo, Norway., Mælandsmo GM; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Ullernchausseen 70, 0379, Oslo, Norway. g.m.malandsmo@ous-research.no.; Department of Medical Biology, Faculty of Health Sciences, UiT/The Arctic University of Norway, Tromsø, Norway. g.m.malandsmo@ous-research.no., Seip K; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Ullernchausseen 70, 0379, Oslo, Norway. kotryna.seip@rr-research.no.

المصدر: Scientific reports [Sci Rep] 2022 Mar 24; Vol. 12 (1), pp. 5076. Date of Electronic Publication: 2022 Mar 24.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

مواضيع طبية MeSH: Melanoma*/pathology , Skin Neoplasms*/pathology, Cell Line, Tumor ; Drug Resistance, Neoplasm ; Humans ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins B-raf/genetics ; Vemurafenib/pharmacology

المؤلفون: Normann LS; Department of Research and Innovation, Vestre Viken Hospital Trust, P.O. Box 800, 3004, Drammen, Norway.; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Aure MR; Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Leivonen SK; Applied Tumor Genomics Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland., Haugen MH; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Hongisto V; Division of Toxicology, Misvik Biology, Turku, Finland., Kristensen VN; Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Division of Medicine, Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway., Mælandsmo GM; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Institute for Medical Biology, Faculty of Health Sciences, UiT-The Arctic University of Norway, Tromsø, Norway., Sahlberg KK; Department of Research and Innovation, Vestre Viken Hospital Trust, P.O. Box 800, 3004, Drammen, Norway. Kristine.Sahlberg@vestreviken.no.; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. Kristine.Sahlberg@vestreviken.no.

المصدر: Scientific reports [Sci Rep] 2021 May 25; Vol. 11 (1), pp. 10893. Date of Electronic Publication: 2021 May 25.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms/*genetics , Gene Expression Profiling/*methods , Lapatinib/*pharmacology , MicroRNAs/*genetics , Trastuzumab/*pharmacology, Breast Neoplasms/drug therapy ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Prognosis ; Survival Analysis ; Up-Regulation

المؤلفون: Haugen MH; Department of Tumor Biology, Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway., Lingjærde OC; Department of Genetics, Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.; Department of Informatics-Biomedical Informatics, University of Oslo, Oslo, Norway.; K.G. Jebsen-Centre for B Cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Hedenfalk I; Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden., Garred Ø; Division of Laboratory Medicine-Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway., Borgen E; Division of Laboratory Medicine-Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway., Loman N; Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Skåne, Sweden., Hatschek T; Department of Oncology-Pathology, Karolinska University Hospital, Stockholm, Sweden., Børresen-Dale AL; Department of Genetics, Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Naume B; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Mills GB; Department of Cell, Developmental and Cancer Biology, School of Medicine, Oregon Health Science University, Portland, OR., Mælandsmo GM; Department of Tumor Biology, Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.; Institute for Medical Biology, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway., Engebraaten O; Department of Tumor Biology, Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.

المصدر: JCO precision oncology [JCO Precis Oncol] 2021 Jan 28; Vol. 5. Date of Electronic Publication: 2021 Jan 28 (Print Publication: 2021).

نوع المنشور: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: eCollection Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol

مواضيع طبية MeSH: Neoadjuvant Therapy*, Antineoplastic Agents, Immunological/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Bevacizumab/*therapeutic use , Breast Neoplasms/*drug therapy, Breast Neoplasms/chemistry ; Female ; Humans ; Neoplasm Proteins ; Predictive Value of Tests ; Receptor, ErbB-2/analysis ; Treatment Outcome